Blog NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines? Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise. Skin Cancer Drug Effective in Mice with Alzheimer’s, Should We Prescribe Off-Label? Nov 12, 2012 Should a drug that’s effective in animals against the underlying pathology of Alzheimer’s, but proven safe in humans for leukemia be prescribed off-label? AstraZeneca, Unraveling the Neuroscience of Alzheimer’s Nov 05, 2012 For November’s focus on Alzheimer’s, we’re featuring an article written by an AstraZeneca scientist, published on their new company blog, Lab Talk. Breast Cancer Survivors Find Support on Twitter Oct 30, 2012 As Eureka wraps up its series on cancer research innovation in honor of Breast Cancer Awareness Month, we wanted to point out how the cancer patient community is using social media to unite and share resources. Improving Cancer Drugs with Animal “Avatars” Oct 22, 2012 Patient-derived tumor xenografts show promise in the early evaluation of potential cancer therapies. Magic Bullets: The Next Evolution in Targeted Cancer Therapy Oct 16, 2012 New ‘armed antibodies’ represent proverbial magic bullets–envisioned by a Nobel Laureate 100 years ago–killing tumors with greater efficacy and fewer side effects. Transgenic Mouse Models as Alternatives to the 2-Year Mouse Bioassay Oct 08, 2012 Formerly regarded as an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay. Displaying results 41-50 (of 91) |< < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 > >|
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise.
Skin Cancer Drug Effective in Mice with Alzheimer’s, Should We Prescribe Off-Label? Nov 12, 2012 Should a drug that’s effective in animals against the underlying pathology of Alzheimer’s, but proven safe in humans for leukemia be prescribed off-label?
AstraZeneca, Unraveling the Neuroscience of Alzheimer’s Nov 05, 2012 For November’s focus on Alzheimer’s, we’re featuring an article written by an AstraZeneca scientist, published on their new company blog, Lab Talk.
Breast Cancer Survivors Find Support on Twitter Oct 30, 2012 As Eureka wraps up its series on cancer research innovation in honor of Breast Cancer Awareness Month, we wanted to point out how the cancer patient community is using social media to unite and share resources.
Improving Cancer Drugs with Animal “Avatars” Oct 22, 2012 Patient-derived tumor xenografts show promise in the early evaluation of potential cancer therapies.
Magic Bullets: The Next Evolution in Targeted Cancer Therapy Oct 16, 2012 New ‘armed antibodies’ represent proverbial magic bullets–envisioned by a Nobel Laureate 100 years ago–killing tumors with greater efficacy and fewer side effects.
Transgenic Mouse Models as Alternatives to the 2-Year Mouse Bioassay Oct 08, 2012 Formerly regarded as an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay.
